EU medtech industry urges caution over pace and type of change
This article was originally published in SRA
European medical technology association Eucomed feels that the European Commission is not aware of how complex and difficult issues relating to the industry and medical device regulation will get in the next 15 to 20 years. The commission’s approach towards tackling emerging issues – as reflected in its consultation on a potential recast of the medical device directive – suggests that it is moving too fast without all the information it needs, Eucomed believes1,2.
You may also be interested in...
A UK regulator with the MHRA is concerned that bioanalytical laboratories are not being given enough time to do their job properly by drug companies under pressure to ensure their clinical trials remain on schedule.
The UK regulator is expecting a rise in amendments and deviations to ongoing clinical investigations of medical devices due to the COVID-19 pandemic and has issued advice on how companies should manage these.
Work and movement-related restrictions are affecting the ability of companies to provide a timely response to questions relating to their prequalification dossiers.